Results 121 to 130 of about 22,694 (264)

RISKS AND BENEFITS OF ORAL HORMONAL CONTRACEPTION

Zdravniški Vestnik, 2018
Background: Oral hormonal contraception (OC) or the birth control pill that has been in use since 1960 is considered an efficient and reliable method of pregnancy prevention. In the early days the pill contained high doses of hormones, and the related complications were frequently reported.
openaire   +1 more source

An evolutionary medicine perspective on the design of non-hormonal contraceptives for women. [PDF]

Evol Med Public Health
Place NJ, Yan W.
europepmc   +1 more source

Unveiling Gut Homeostasis Disruption in Sepsis: Towards an Integrated Mechanistic and Translational Roadmap

Cell Proliferation, EarlyView.
Elucidating the contribution of gut‐organ axes will provide new insights for developing combined therapeutic strategies against sepsis‐associated multiple organ dysfunction. ABSTRACT Sepsis, a life‐threatening clinical syndrome precipitated by a maladaptive host response to infection, is associated with substantial morbidity and high mortality rates ...
Yichen Bao, Lin Qi, Guijun Zou, Xingpeng Yang, Yizhao Ma, Zhifu Li, Xiaohui Du, Pengyue Zhao   +7 more
wiley   +1 more source

Oral Contraceptives: Hormones and Coagulation [PDF]

Nature, 1969
openaire   +1 more source

Prevalence of Depression Among Women Using Hormonal Contraceptives in Mogadishu, Somalia: A Cross-Sectional Study

Open Access Journal of Contraception
Abdirizak Mohamud Yusuf,1 Mohamed Omar Warsame,2 Saido Gedi,3 Naima Abdulkarim Abdullahi,4 Daud Ibrahim Ahmed5 1Department of Family Health, Federal Ministry of Health, Mogadishu, Somalia; 2School of Public Health and Research, Somali National University,
Yusuf AM, Warsame MO, Gedi S, Abdullahi NA, Ahmed DI   +4 more
doaj  

Hormonal contraceptives and EEG biomarkers for antidepressant treatment response in women. [PDF]

Commun Med (Lond)
Jensen KHR, Juvik AK, Larsen SV, Andersen MT, Frokjaer VG, Jørgensen MB, Ip CT.   +6 more
europepmc   +1 more source

A Tale as Old as Time: Contraception Concerns in the 21st Century. [PDF]

Open Access J Contracept
Bottomley-Wise RM, Woodward A, Okanlawon A, Mason-Jones AJ.   +3 more
europepmc   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

Prescribed hormonal contraceptive use trends in the Estonian Biobank: A longitudinal observational study. [PDF]

PLoS Med
Džigurski J, Möls M, Läll K, Currant H, Eltermaa M, Estonian Biobank Research Team, Mägi R, Milani L, Laisk T.   +8 more
europepmc   +1 more source

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m2 and at least one obesity‐related complication) or obesity (BMI ≥ 30 kg/m2), without diabetes, using data ...
Wojciech Michalak, Martin Bøg, Theiss Bendixen, Rohan Chowdhury, Phoebe Cowley, Christian Laugesen, Naveen Rathor, Robert F. Kushner   +7 more
wiley   +1 more source